Oral GLP-1 Pills Deliver Double-Digit Weight Loss in Major Phase-3 Trials
Two landmark NEJM trials show oral GLP-1 drugs achieve 11–14% weight loss, potentially eliminating the need for injections.
296 articles in this topic
Two landmark NEJM trials show oral GLP-1 drugs achieve 11–14% weight loss, potentially eliminating the need for injections.
A phase 1 trial shows tirzepatide slashes ad libitum calorie intake by over 500 kcal at a single meal while blunting brain reward responses to junk food.
A new review weighs the benefits and dangers of using GLP-1 and GIP/GLP-1 therapies in older adults with sarcopenic obesity.
A pilot RCT tests whether semaglutide can optimize obese patients before and after total knee arthroplasty, targeting a critical gap in perioperative care.
A large Chinese cohort study identifies a nutrient-dense eating pattern linked to significantly lower metabolic syndrome odds.
A new real-world study finds semaglutide significantly reduces blood eosinophil levels, with the strongest effect in non-obese individuals.
A sweeping 2025 review reveals ghrelin's roles span immunity, neuroprotection, cardiovascular health, and addiction beyond appetite.
Deleting GHSR in macrophages cuts liver fibrosis markers and inflammation in mice, revealing a druggable signaling axis.
Adenosine 5'-monophosphate preserves muscle mass during sepsis by activating AMPK and blocking IL-1β, offering a potential new therapy.
Imaging 16 million pancreatic cells reveals macrophage-T cell interactions and beta-cell stress signatures at the earliest, preclinical stages of type 1 diabetes.
A new PTM called lysine pyruvylation links glycolytic activity directly to gene regulation, with SIRT3 acting as the eraser.
A 745-person genomic study identifies why metformin concentrations vary so widely — with ancestry-specific genetic variants playing a key role.